Last reviewed · How we verify

TAP block with Bupivacaine at 0.25%

Patricia Salazar Villegas · FDA-approved active Small molecule

TAP block with Bupivacaine at 0.25% is a Local anesthetic Small molecule drug developed by Patricia Salazar Villegas. It is currently FDA-approved for Postoperative analgesia following abdominal surgery, Regional anesthesia for abdominal wall anesthesia. Also known as: TAP block, Infiltration of local anesthetic, Local anesthesia in inguinal herniorrhaphy.

Bupivacaine blocks sodium channels in nerve fibers to provide local anesthesia when infiltrated into the transversus abdominis plane (TAP).

Bupivacaine blocks sodium channels in nerve fibers to provide local anesthesia when infiltrated into the transversus abdominis plane (TAP). Used for Postoperative analgesia following abdominal surgery, Regional anesthesia for abdominal wall anesthesia.

At a glance

Generic nameTAP block with Bupivacaine at 0.25%
Also known asTAP block, Infiltration of local anesthetic, Local anesthesia in inguinal herniorrhaphy
SponsorPatricia Salazar Villegas
Drug classLocal anesthetic
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia/Pain Management
PhaseFDA-approved

Mechanism of action

The TAP block is a regional anesthesia technique where bupivacaine is injected into the fascial plane between the internal oblique and transversus abdominis muscles, targeting sensory nerves that supply the abdominal wall. At 0.25% concentration, bupivacaine reversibly inhibits sodium influx through voltage-gated sodium channels in nerve cell membranes, preventing action potential propagation and resulting in local anesthesia of the abdominal wall. This technique provides postoperative analgesia for abdominal surgical procedures.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about TAP block with Bupivacaine at 0.25%

What is TAP block with Bupivacaine at 0.25%?

TAP block with Bupivacaine at 0.25% is a Local anesthetic drug developed by Patricia Salazar Villegas, indicated for Postoperative analgesia following abdominal surgery, Regional anesthesia for abdominal wall anesthesia.

How does TAP block with Bupivacaine at 0.25% work?

Bupivacaine blocks sodium channels in nerve fibers to provide local anesthesia when infiltrated into the transversus abdominis plane (TAP).

What is TAP block with Bupivacaine at 0.25% used for?

TAP block with Bupivacaine at 0.25% is indicated for Postoperative analgesia following abdominal surgery, Regional anesthesia for abdominal wall anesthesia.

Who makes TAP block with Bupivacaine at 0.25%?

TAP block with Bupivacaine at 0.25% is developed and marketed by Patricia Salazar Villegas (see full Patricia Salazar Villegas pipeline at /company/patricia-salazar-villegas).

Is TAP block with Bupivacaine at 0.25% also known as anything else?

TAP block with Bupivacaine at 0.25% is also known as TAP block, Infiltration of local anesthetic, Local anesthesia in inguinal herniorrhaphy.

What drug class is TAP block with Bupivacaine at 0.25% in?

TAP block with Bupivacaine at 0.25% belongs to the Local anesthetic class. See all Local anesthetic drugs at /class/local-anesthetic.

What development phase is TAP block with Bupivacaine at 0.25% in?

TAP block with Bupivacaine at 0.25% is FDA-approved (marketed).

What are the side effects of TAP block with Bupivacaine at 0.25%?

Common side effects of TAP block with Bupivacaine at 0.25% include Local tissue toxicity or hematoma at injection site, Systemic toxicity (if intravascular injection), Temporary motor weakness of abdominal muscles.

What does TAP block with Bupivacaine at 0.25% target?

TAP block with Bupivacaine at 0.25% targets Voltage-gated sodium channels and is a Local anesthetic.

Related